Anti-angiogenesis therapy has been greatly investigated since the 1970s when Folkman first put forward that targeting the angiogenesis could interfere in tumorigenesis.[6] Vascular endothelial growth factor (VEGF) protein members and their receptors may be the most crucial factors involved in angiogenesis in malignant tumors. The gene discussed is VEGFA; the disease is cancer.